May 12, 2026

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...

The ASCO Post

April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–posit...

The ASCO Post

April 29, 2026

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC

As reported in the Journal of Clinical Oncology by Li et al, long-term follow-up of a Chinese phase II trial (TRUST-I) showed prolonged activity with taletrectinib in patients with ROS1 mutation–posit...

The ASCO Post

April 14, 2026

Surgery Still Safe, Beneficial For Many Octogenarian Patients With NSCLC

Surgical treatment was found to be safe and demonstrate long-term quality-of-life benefits for carefully selected octogenarians with early-stage non–small cell lung cancer (NSCLC), according to findin...

The ASCO Post

April 14, 2026

Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment

“This randomized phase II study demonstrated that 30 Gy in one fraction was equivalent to 60 Gy in three fractions in terms of toxicity, local failure, freedom from distal failure, progression-free su...

The ASCO Post

April 07, 2026

Two Major Cancer Centers Announce Appointments of New Directors

Last week, Dartmouth Cancer Center and Fox Chase Cancer Center announced the appointments of new directors—both experts in the treatment of lung cancer.

The ASCO Post

March 23, 2026

Temple Lung Center | Enrolling Clinical Trials

The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.

Temple Health

February 27, 2026

2024–2025 Drug Updates in Solid Tumors

Jadpro

February 18, 2026

Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC

When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic c...

The ASCO Post

January 28, 2026

Associations Found Between Air Pollutants and Lung Cancer Subtypes

Both particulate and gaseous air pollutants were linked with subtypes of lung cancer in research published in Environmental Pollution. The analysis showed that nitrogen dioxide was associated with ade...

The ASCO Post